Truist raised the firm’s price target on Fresenius Medical (FMS) to $28 from $26 and keeps a Hold rating on the shares. Despite the non-discretionary nature of the service and solid cash flow, improving volume trends remain critical amid a mixed environment marked by sluggish admissions, mortality, and missed treatments, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical price target lowered to EUR 37 from EUR 39 at Morgan Stanley
- Cautious Outlook for Fresenius Medical Care Amid Sector Challenges and Persistent Headwinds
- Fresenius Medical Care Appoints New Global Chief Medical Officer
- Fresenius Medical names Charles Hugh-Jones as Global Chief Medical Officer
- Fresenius Medical price target lowered to EUR 37.40 from EUR 41.50 at JPMorgan